|
HUE055755T2
(hu)
|
2015-02-16 |
2021-12-28 |
Univ Queensland |
Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk
|
|
CA3002369A1
(en)
|
2015-10-20 |
2017-04-27 |
Magic Leap, Inc. |
Selecting virtual objects in a three-dimensional space
|
|
KR20230098927A
(ko)
|
2016-03-31 |
2023-07-04 |
매직 립, 인코포레이티드 |
포즈들 및 멀티-dof 제어기들을 사용하는 3d 가상 객체들과상호작용들
|
|
CA3047336A1
(en)
|
2017-01-23 |
2018-07-26 |
Jecure Therapeutics, Inc. |
Chemical compounds as inhibitors of interleukin-1 activity
|
|
US10768693B2
(en)
|
2017-04-19 |
2020-09-08 |
Magic Leap, Inc. |
Multimodal task execution and text editing for a wearable system
|
|
KR102669722B1
(ko)
|
2017-07-07 |
2024-05-29 |
인플라좀 리미티드 |
신규한 설폰아마이드 카복스아마이드 화합물
|
|
HUE066566T2
(hu)
|
2017-07-24 |
2024-08-28 |
Novartis Ag |
Vegyületek és készítmények NLRP aktivitással összefüggõ állapotok kezelésére
|
|
EP3658538B1
(en)
*
|
2017-07-24 |
2023-04-19 |
Novartis AG |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
TW201910317A
(zh)
|
2017-08-15 |
2019-03-16 |
愛爾蘭商英弗雷佐姆有限公司 |
新穎化合物
|
|
TW201910316A
(zh)
*
|
2017-08-15 |
2019-03-16 |
愛爾蘭商英弗雷佐姆有限公司 |
新穎化合物
|
|
EP3668843A1
(en)
|
2017-08-15 |
2020-06-24 |
Inflazome Limited |
Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
|
|
WO2019043610A1
(en)
|
2017-08-31 |
2019-03-07 |
Cadila Healthcare Limited |
NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
|
|
JP7157804B2
(ja)
*
|
2017-10-17 |
2022-10-20 |
ノバルティス アーゲー |
Ｎｌｒｐ活性に関連する病態を治療するためのスルホンアミド及びその組成物
|
|
PE20210050A1
(es)
|
2017-11-09 |
2021-01-08 |
Inflazome Ltd |
Nuevos compuestos de sulfonamida carboxamida
|
|
EP3707137A1
(en)
|
2017-11-09 |
2020-09-16 |
Inflazome Limited |
Novel sulfonamide carboxamide compounds
|
|
US12030879B2
(en)
|
2018-03-02 |
2024-07-09 |
Inflazome Limited |
Sulfonyl acetamides as NLRP3 inhibitors
|
|
EP3759073A1
(en)
|
2018-03-02 |
2021-01-06 |
Inflazome Limited |
Sulfonamide derivates as nlrp3 inhibitors
|
|
US11884645B2
(en)
|
2018-03-02 |
2024-01-30 |
Inflazome Limited |
Sulfonyl acetamides as NLRP3 inhibitors
|
|
EP3759089A1
(en)
*
|
2018-03-02 |
2021-01-06 |
Inflazome Limited |
Novel compounds
|
|
GB201803393D0
(en)
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
GB201803394D0
(en)
|
2018-03-02 |
2018-04-18 |
Inflazome Ltd |
Novel compounds
|
|
US11530200B2
(en)
|
2018-03-02 |
2022-12-20 |
Inflazome Limited |
Compounds
|
|
WO2019166619A1
(en)
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Novel compounds
|
|
WO2019166627A1
(en)
|
2018-03-02 |
2019-09-06 |
Inflazome Limited |
Novel compounds
|
|
GB201806578D0
(en)
|
2018-04-23 |
2018-06-06 |
Inflazome Ltd |
Novel compound
|
|
MA52489A
(fr)
|
2018-05-04 |
2021-03-10 |
Inflazome Ltd |
Nouveaux composés
|
|
CA3103664A1
(en)
|
2018-07-03 |
2020-01-09 |
Novartis Ag |
Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist
|
|
JP2021529186A
(ja)
*
|
2018-07-03 |
2021-10-28 |
ノバルティス アーゲー |
Ｎｌｒｐ調節剤
|
|
CA3104199A1
(en)
|
2018-07-20 |
2020-01-23 |
F. Hoffmann-La Roche Ag |
Sulfonylurea compounds as inhibitors of interleukin-1 activity
|
|
BR112021001044A2
(pt)
|
2018-07-20 |
2021-04-13 |
F. Hoffmann-La Roche Ag |
Compostos de sulfonimidamida como inibidores da atividade de interleucina-1
|
|
CN112672995A
(zh)
|
2018-08-15 |
2021-04-16 |
英夫拉索姆有限公司 |
新型磺酰胺脲化合物
|
|
GB201902327D0
(en)
|
2019-02-20 |
2019-04-03 |
Inflazome Ltd |
Novel compounds
|
|
JP2022505562A
(ja)
*
|
2018-10-24 |
2022-01-14 |
ノバルティス アーゲー |
Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
|
|
ES2974842T3
(es)
*
|
2018-11-13 |
2024-07-01 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de nlrp
|
|
ES2957692T3
(es)
|
2018-11-13 |
2024-01-24 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
|
|
WO2020102574A1
(en)
*
|
2018-11-16 |
2020-05-22 |
Novartis Inflammasome Research, Inc. |
The compounds and compositions for treating conditions associated with nlrp activity
|
|
GB201819083D0
(en)
|
2018-11-23 |
2019-01-09 |
Inflazome Ltd |
Novel compounds
|
|
EP3914583A1
(en)
*
|
2019-01-22 |
2021-12-01 |
Novartis AG |
Compounds and compositions for treating conditions associated with nlrp activity
|
|
GB201905265D0
(en)
|
2019-04-12 |
2019-05-29 |
Inflazome Ltd |
Inflammasome inhibition
|
|
US20220267300A1
(en)
*
|
2019-06-12 |
2022-08-25 |
NodThera Limited |
Sulfonamide derivatives and uses thereof
|
|
EP3986879B1
(en)
|
2019-06-21 |
2024-10-02 |
AC Immune SA |
Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators
|
|
AU2020314186B2
(en)
*
|
2019-07-17 |
2026-04-23 |
Zomagen Biosciences Ltd |
NLRP3 modulators
|
|
JP7723652B2
(ja)
|
2019-07-17 |
2025-08-14 |
ズーマゲン バイオサイエンシーズ エルティーディー |
多発性硬化症（ＭＳ）の治療のためのＮＬＰＲ３モジュレーターとしてのＮ－（（１，２，３，５，６，７－ヘキサヒドロ－ｓ－インダセン－４－イル）カルバモイル）－４，５，６，７－テトラヒドロベンゾフラン－２－スルホンアミド誘導体および関連化合物
|
|
TW202115095A
(zh)
*
|
2019-08-16 |
2021-04-16 |
愛爾蘭商英弗雷佐姆有限公司 |
新穎化合物
|
|
JP2022547882A
(ja)
|
2019-09-06 |
2022-11-16 |
インフレイゾーム リミテッド |
Ｎｌｒｐ３阻害剤
|
|
JP7843705B2
(ja)
|
2020-01-22 |
2026-04-10 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物
|
|
US11618751B1
(en)
|
2022-03-25 |
2023-04-04 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
|
|
EP4121059A4
(en)
|
2020-03-16 |
2023-12-13 |
Zomagen Biosciences Ltd |
NLRP3 MODULATORS
|
|
CN121177307A
(zh)
*
|
2020-03-19 |
2025-12-23 |
南洋理工大学 |
包含nlrp1炎性体激活抑制剂的化合物或组合物用于治疗人气道炎症的用途
|
|
ES3064621T3
(en)
*
|
2020-03-27 |
2026-04-27 |
Tenvie Therapeutics Inc |
Substituted pyridazine compound
|
|
CN111419842A
(zh)
*
|
2020-04-24 |
2020-07-17 |
南方医科大学南方医院 |
炎症小体抑制剂cy-09用于制备治疗非酒精性脂肪性肝炎的药物的用途
|
|
JP7504234B2
(ja)
*
|
2020-06-11 |
2024-06-21 |
シーセン ファーマシューティカル カンパニー リミテッド |
ジメチルスルホキシミン誘導体
|
|
IL299084A
(en)
|
2020-06-19 |
2023-02-01 |
Ac Immune Sa |
History of dihydrooxazole and thiourea or urea modulating the NLRP3 inflammasome pathway
|
|
WO2022022646A1
(zh)
*
|
2020-07-29 |
2022-02-03 |
南京明德新药研发有限公司 |
含硒五元杂芳环化合物
|
|
WO2022023907A1
(en)
|
2020-07-31 |
2022-02-03 |
Novartis Ag |
Methods of selecting and treating patients at elevated risk of major adverse cardiac events
|
|
US11319319B1
(en)
|
2021-04-07 |
2022-05-03 |
Ventus Therapeutics U.S., Inc. |
Compounds for inhibiting NLRP3 and uses thereof
|
|
US11932630B2
(en)
|
2021-04-16 |
2024-03-19 |
Novartis Ag |
Heteroaryl aminopropanol derivatives
|
|
BR112023022451A2
(pt)
|
2021-04-28 |
2024-01-02 |
Astellas Pharma Inc |
Composto triazina substituído
|
|
TW202319055A
(zh)
|
2021-07-21 |
2023-05-16 |
日商安斯泰來製藥股份有限公司 |
縮環噠嗪（ｐｙｒｉｄａｚｉｎｅ）化合物
|
|
CN114213358A
(zh)
*
|
2021-12-22 |
2022-03-22 |
上海泰坦科技股份有限公司 |
一种2-溴-5-甲醛基噻唑的合成方法
|
|
US20250109126A1
(en)
|
2021-12-22 |
2025-04-03 |
Ac Immune Sa |
Dihydro-oxazol derivative compounds
|
|
EP4554945A1
(en)
|
2022-07-14 |
2025-05-21 |
AC Immune SA |
Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway
|
|
CA3261365A1
(en)
|
2022-07-28 |
2024-02-01 |
Ac Immune Sa |
NEW COMPOUNDS
|
|
TW202432551A
(zh)
|
2022-10-26 |
2024-08-16 |
日商安斯泰來製藥股份有限公司 |
稠環嗒嗪衍生物
|
|
US12331048B2
(en)
|
2022-10-31 |
2025-06-17 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
|
|
JP2026510921A
(ja)
*
|
2023-03-17 |
2026-04-10 |
ヴェンタス・セラピューティクス・ユー・エス・インコーポレイテッド |
Ｎｌｒｐ３を阻害するためのアミド誘導体及びその使用
|
|
EP4719599A1
(en)
|
2023-06-02 |
2026-04-08 |
Merck Sharp & Dohme LLC |
5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3
|
|
WO2025133307A1
(en)
|
2023-12-22 |
2025-06-26 |
Ac Immune Sa |
Heterocyclic modulators of the nlrp3 inflammasome pathway
|
|
WO2025153532A1
(en)
|
2024-01-16 |
2025-07-24 |
NodThera Limited |
Nlrp3 inhibitors and glp-1 agonists combination therapies
|
|
WO2025153624A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025153625A1
(en)
|
2024-01-17 |
2025-07-24 |
Ac Immune Sa |
Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
|
|
WO2025163069A1
(en)
|
2024-01-31 |
2025-08-07 |
Ac Immune Sa |
Novel compounds
|
|
WO2026057747A1
(en)
|
2024-09-11 |
2026-03-19 |
Ac Immune Sa |
Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds
|